- Home
- SAVA vs ANIX Comparison
SAVA vs ANIX Comparison
Compare SAVA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- ANIX
- Stock Information
- Founded
- SAVA 1998
- ANIX 1982
- Country
- SAVA United States
- ANIX United States
- Employees
- SAVA N/A
- ANIX N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- ANIX Health Care
- Exchange
- SAVA Nasdaq
- ANIX Nasdaq
- Market Cap
- SAVA 102.4M
- ANIX 95.7M
- IPO Year
- SAVA N/A
- ANIX 1987
- Fundamental
- Price
- SAVA $3.63
- ANIX $3.27
- Analyst Decision
- SAVA Hold
- ANIX Strong Buy
- Analyst Count
- SAVA 1
- ANIX 3
- Target Price
- SAVA $2.00
- ANIX $9.00
- AVG Volume (30 Days)
- SAVA 4.9M
- ANIX 146.1K
- Earning Date
- SAVA 11-06-2025
- ANIX 09-10-2025
- Dividend Yield
- SAVA N/A
- ANIX N/A
- EPS Growth
- SAVA N/A
- ANIX N/A
- EPS
- SAVA N/A
- ANIX N/A
- Revenue
- SAVA N/A
- ANIX N/A
- Revenue This Year
- SAVA N/A
- ANIX N/A
- Revenue Next Year
- SAVA N/A
- ANIX N/A
- P/E Ratio
- SAVA N/A
- ANIX N/A
- Revenue Growth
- SAVA N/A
- ANIX N/A
- 52 Week Low
- SAVA $1.15
- ANIX $2.07
- 52 Week High
- SAVA $33.98
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- ANIX 50.55
- Support Level
- SAVA $2.85
- ANIX $3.21
- Resistance Level
- SAVA $3.66
- ANIX $3.44
- Average True Range (ATR)
- SAVA 0.34
- ANIX 0.16
- MACD
- SAVA 0.10
- ANIX -0.01
- Stochastic Oscillator
- SAVA 92.90
- ANIX 15.38
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.